Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 14/20 | 0.77 |
| ▸ | CHRNB2 | P17787 | 14/20 | 0.77 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6208049 | 0.99 | CHRNA7 (0.76) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372648 | 0.87 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL6209191 | 0.83 | CHRNA7 (0.63) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL28838840 | 0.82 | CHRNA7 (0.62) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373001 | 0.81 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL13240100 | 0.80 | CHRNA7 (0.81) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373208 | 0.80 | CHRNB2 (0.88) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372864 | 0.78 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL834978 | 0.78 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372691 | 0.76 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389208-B1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) | PHARMACIA & UPJOHN CO LLC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | claimed |
| EP-1389208-A1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-20 | — | — | US | claimed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| WO-2002085901-A1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | CHRNA1, CHRNA7, CHRNA5 | CHRNA7 2/4885CHRNB2 10/4885CHRNA4 12/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CHRNA7 4467/4885CHRNB2 3665/4885CHRNA4 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.